Arcus Biosciences Total Assets 2017-2022 | RCUS
Arcus Biosciences total assets from 2017 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Arcus Biosciences Annual Total Assets
(Millions of US $) |
| 2022 |
$1,345 |
| 2021 |
$1,592 |
| 2020 |
$772 |
| 2019 |
$203 |
| 2018 |
$275 |
| 2017 |
$190 |
| 2016 |
$0 |
Arcus Biosciences Quarterly Total Assets
(Millions of US $) |
| 2022-12-31 |
$1,345 |
| 2022-09-30 |
$1,394 |
| 2022-06-30 |
$1,477 |
| 2022-03-31 |
$1,543 |
| 2021-12-31 |
$1,592 |
| 2021-09-30 |
$839 |
| 2021-06-30 |
$899 |
| 2021-03-31 |
$935 |
| 2020-12-31 |
$772 |
| 2020-09-30 |
$811 |
| 2020-06-30 |
$481 |
| 2020-03-31 |
$176 |
| 2019-12-31 |
$203 |
| 2019-09-30 |
$217 |
| 2019-06-30 |
$239 |
| 2019-03-31 |
$259 |
| 2018-12-31 |
$275 |
| 2018-09-30 |
$287 |
| 2018-06-30 |
$294 |
| 2018-03-31 |
$305 |
| 2017-12-31 |
$190 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.286B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
